vip236

Phase 1 Dose Escalation Study for VIP236 in Patients with Advanced Cancer

DESCRIPTION OF STUDY

This is a Phase 1 dose-escalation study. The purpose of the study is to determine the safety, tolerability, and maximum tolerated dose of VIP236 in patients with advanced solid tumor cancer.

ELIGIBILITY

  • Age: 18+
  • Sex: Both
  • Status: Recruiting